KMT2D and urothelial carcinoma: Erdafitinib, an FGFR inhibitor, is approved for FGFR3-altered urothelial carcinoma, and emerging agents targeting epigenetic alterations such as ARID1A or KMT2D mutations may expand future treatment options (23–25).